Plus Therapeutics (NASDAQ:CNSY) Issues Quarterly Earnings Results, Misses Expectations By $0.35 EPS

Plus Therapeutics (NASDAQ:CNSY) issued its quarterly earnings results on Friday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35), Zacks reports. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%.

Plus Therapeutics Stock Down 0.5%

NASDAQ:CNSY traded down $0.02 during mid-day trading on Friday, hitting $3.68. The company’s stock had a trading volume of 95,231 shares, compared to its average volume of 79,865. The firm has a market capitalization of $25.32 million, a PE ratio of -1.60 and a beta of 1.42. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Weiss Ratings assumed coverage on Plus Therapeutics in a research note on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. Zacks Research cut Plus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.